• 1
    World Health Organization. Global Tuberculosis Control, Surveillance, Planning, Financing. 2012.
  • 2
    Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006;367:117380.
  • 3
    Russell DG, Barry CE, Flynn JL. Tuberculosis: what we don't know can, and does, hurt us. Science 2010;328:8526.
  • 4
    Windish HP, Dytgue MS, Ireton G et al. Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate. Vaccine 2011;44:74828.
  • 5
    Cayabyab MJ, Kashino SS, Campos-Neto A. Robust immune response elicited by a novel and unique Mycobacterium tuberculosis protein using an optimized DNA/protein heterologous prime/boost protocol. Immunology 2012;3:21625.
  • 6
    Juarea-Rodriquez MD, Yang J, Kader R, Alamuri P, CurtissRC 3rd, Lark-Curtiss JE. Live attenuated Salmonella vaccine displaying regulated delayed lysis and delayed antigen synthesis to confer protection against Mycobacterium tuberculosis. Infect Immun 2012;2:81531.
  • 7
    Yang X, Bao L, Deng Y. A novel recombinant Mycobacterium bovis bacillus Calmette-Guerin strain expressing human granulocyte macrophage colony-stimulating factor and Mycobacterium tuberculosis early secretory antigenic target 6 complex augments Th1 immunity. Acta Biochim Biophys Sin (Shanghai) 2011;7:51118.
  • 8
    Kong CU, Ng LG, Nambiar JK, Spratt JM, Weninger W, Triccas JA. Targeted induction of antigen expression within dendritic cells modulates antigen-specific immunity afforded by recombinant BCG. Vaccine 2011;7:137481.
  • 9
    Deng YH, Sun Z, Yang XL, Bao L. Improved immunogenicity of recombinant Mycobacterium bovis bacillus Calmette-Guérin strains expressing fusion protein Ag85A-ESAT-6 of Mycobacterium tuberculosis. Scand J Immunol 2010;4:3328.
  • 10
    Christy AJ, Dharman K, Dhandapaani G et al. Epitope based recombinant BCG vaccine elicits specific Th1 polarized immune responses in BALB/c mice. Vaccine 2012;7:136470.
  • 11
    Billeskov R, Grandal MV, Poulsen C et al. Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis. Eur J Immunol 2010;5:134254.
  • 12
    Huang X, Yu HS, Chen Z, Li JL, Hu ZM, Gao JM. A novel immunotherapy for superficial bladder cancer by the immobilization of streptavidin-tagged bioactive IL-2 on the biotinylated mucosal surface of the bladder wall. Chin J Cancer 2010;6:61116.
  • 13
    Deng Y, Bao L, Yang X. Evaluation of immunogenicity and protective efficacy against Mycobacterium tuberculosis infection elicited by recombinant Mycobacterium bovis BCG expressing human Interleukin-12p70 and Early Secretory Antigen Target-6 fusion protein. Microbiol Immunol 2011;11:798808.
  • 14
    Ryan AA, Wozniak TM, Shklovskaya E et al. Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guerin secreting murine GM-CSF is associated with expansion and activation of APCs. J Immunol 2007;12:841824.
  • 15
    Lin CW, Su J, Chang JR, Chen YY, Lu JJ, Dou HY. Recombinant BCG coexpressing Ag85B, CFP10, and interleukin-12 induces multifunctional Th1 and memory T cells in mice. APMIS 2012;1:7282.
  • 16
    D'Souza S, Rosseels V, Romano M et al. Mapping of murine Th1 helper T-cell epitopes of Mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect Immun 2003;71:48393.
  • 17
    Rosseels V, Marche S, Roupie V et al. Members of the 30- to 32-kilodalton mycolyl transferase family (Ag85) from culture filtrate of Mycobacterium avium subsp. paratuberculosis are immunodominant Th1-type antigens recognized early upon infection in mice and cattle. Infect Immun 2006;74:20212.
  • 18
    Armitige LY, Jagannath C, Wanger AR, Norres SJ. Disruption of the genes encoding antigen 85A and antigen 85B of Mycobacterium tuberculosis H37Rv: effect on growth in culture and in macrophages. Infect Immun 2000;68:76778.
  • 19
    Ha SJ, Park SH, Kim HJ et al. Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination. Infect Immun 2006;74:49549.
  • 20
    Palendira U, Kamath AT, Feng CG et al. Coexpression of interleukin-12 chains by a self-splicing vector increases the protective cellular immune response of DNA and Mycobacterium bovis BCG vaccines against Mycobacterium tuberculosis. Infect Immun 2002;70:194956.
  • 21
    Gerosa F, Paganin C, Peritt D et al. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon gamma and interleukin-10. J Exp Med 1996;183:255969.
  • 22
    Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:13346.
  • 23
    Sai Priya VH, Anuradha B, Latha Gaddam S, Hasnain SE, Murthy KJ, Valluri VL. In vitro levels of interleukin 10 (IL-10) and IL-12 in response to a recombinant 32-kilodalton antigen of Mycobacterium bovis BCG after treatment for tuberculosis. Clin Vaccine Immunol 2009;1:11115.
  • 24
    Radosevic K, Wieland CW, Rodriguez A et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun 2007;8:410515.
  • 25
    Munk ME, Emoto M. Functions of T-cell subsets and cytokines in mycobacterial infections. Eur Respir J Suppl 1995;20:668s75s.
  • 26
    Sud D, Bigbee C, Flynn JL, Kirschner DE. Contribution of CD8+ T cells to control of Mycobacterium tuberculosis infection. J Immunol 2006;176:4296314.
  • 27
    Kawamura I. Protective immunity against Mycobacterium tuberculosis. Kekkaku 2006;11:68791.
  • 28
    Lalvani A, Millington KA. T Cells and Tuberculosis: Beyond Interferon-gamma. J Infect Dis 2008;197:9413.
  • 29
    Rook GA. Th2 cytokine in susceptibility to tuberculosis. Curr Mol Med 2007;7:32737.
  • 30
    Katti MK, Dai G, Armitige LY et al. The Delta fbpA mutant derived from Mycobacterium tuberculosis H37Rv has an enhanced susceptibility to intracellular antimicrobial oxidative mechanisms, undergoes limited phagosome maturation and activates macrophages and dendritic cells. Cell Microbiol 2008;10:1286303.